San Francisco Partner Judith Waltz was quoted in an article titled “Sunshine Act Compliance Stymies Healthcare Firms” in the July 2013 issue of Compliance Week. The article discusses the impact the Sunshine Act will have on drug companies and medical equipment companies. Ms. Waltz was quoted saying, “This may relate to concerns about how their participation will be viewed by patients, or to the increasing prevalence of institutional policies that limit or even preclude involvement in any activity that might be viewed as a conflict of interest for clinical decision making. [If this trend continues,] it could result in some significant constrictions on future research and clinical discussion of existing drugs.”
People
Related News
July 24, 2025
In the News
Foley's Trial Team Featured Following Landmark Victory in Texas Trade Secret Case
Foley & Lardner LLP’s recent landmark appellate victory in a Texas trade secrets case is featured in the Texas Lawyer article, "Ruling Sets Precedent for Employment, Trade Secrets, Fiduciary Duty."
July 24, 2025
In the News
Gregory Husisian and David Simon on Tariff Evasion – 'Huge money at stake'
Foley & Lardner LLP partners Gregory Husisian and David Simon detailed the rise and risks of tariff evasion in the POLITICO article, "As Trump raises tariffs, companies find ways to cheat — and risk getting caught."
July 23, 2025
In the News
Aaron Maguregui on AI Scribes in Health Care – 'Technically, it's a third party listening'
Foley & Lardner LLP partner Aaron Maguregui shared insights on the growing applications for artificial intelligence across health care in the healthleaders article, “Is Your AI Scribe HIPAA-Compliant?“